

## **BioDan Group will announce at the ARM meeting in NY their growth plans and new product strategy**

**Madrid, 18<sup>th</sup> March 2015**

The BioDan Group will announce their growth plans based in the new products coming into the market and the revenue growth projections due to their pipeline in new product development. BioDan will announce several growth areas:

- **SkinMed:** BioDan autologous bioactive skin and oral mucosa that will be soon into the market, focused on severe burns and wounds with loss of substance, together with maxillofacial and plastic surgery reconstructions. BioDan Group will announce as well their newly approved Orphan Drug for Epidermolysis bullosa based on BioDan's bioactive skin with mesenchymal cells, where we are launching a multi-centric, multi-country, clinical trial.
- **BioPrinting:** BioDan Group will announce its present success with skin bioprinting and their patented "bioinks" with already preclinical successful results. BioDan will announce as well their present development plans for the printing of 3D organs with the addition of new scaffolds.
- **BioDan's osteogenic albumin scaffold:** New product based on albumin scaffold together with bone and mesenchymal cells coming from the patient. Cells are obtained before or at the same surgical act, from bone cell and marrow extract and the patient's grease extraction to obtain stem mesenchymal cells. Cells differentiate then into bone under the presence of any albumin scaffold. In addition, under the wide public support the IMIDA is pursuing to include fibroin in scaffolds for tissue engineering, BioDan's albumin scaffold is presently under evaluation for maxillofacial bone reconstruction and being tested with or without a fibroin structure to provide albumin an inner skeleton.

All the above products and projects are protected under BioDan Group's licensed patents, and are developed with the support and collaboration of the CIEMAT and the CCSTA, Institutions where the original patents were created.